MUNICH, May 10, 2025 /PRNewswire/ -- At this year's Intersolar Europe, Solavita, the solar energy brand under Skyworth Group, made a strong impression by unveiling new innovations in both commercial and residential energy solutions. Exhibiting a full range of modules, mounting systems, inverters and energy storage systems, Solavita demonstrated growing commitment to driving smarter, more flexible, and sustainable energy systems worldwide.
Launching the 30–50kW Hybrid Inverter for Commercial Projects
Solavita, ranked among the Top 2 Distributed PV Brands in China, proudly introduced new 30–50kW hybrid inverter, designed specifically for commercial solar projects. Built to meet the evolving demands of distributed energy, the inverter brings advanced features that deliver higher efficiency, greater flexibility, and enhanced system protection.
The new hybrid inverter is equipped with up to five MPPTs and supports 2x PV oversizing, maximizing energy capture even in complex rooftop scenarios. On the storage side, it offers three independent 55A battery inputs, supporting both 3-in-1 and separate battery configurations, and is fully compatible with 280 / 314Ah battery— ensuring seamless adaptability across projects.
Engineered for reliability, the inverter delivers 100% unbalanced output and supports 2x rated power input, ensuring stable operation under varying load conditions. It also includes a GEN port, providing more options for diesel generator integration, smart load management, or AC-coupled expansion.
Safety and durability were key design priorities: with smart RSD connectivity, optional AFCI, and an IP66 rating, the inverter is prepared for a wide range of installation environments. Operating at noise levels below 60dB, it's also a perfect fit for projects with strict noise requirements.
This launch marks another important milestone in Solavita's mission to deliver smarter, cleaner energy to businesses around the world.
Recognized as a Top Inverter Innovator by EUPD Research
In recognition of the continuous investment in technology and innovation, Solavita proudly received the "Top Inverter Innovator" and "Sustainable Exhibitor" award from EUPD Research during Intersolar Europe. These awards highlight Solavita's position as a forward-thinking brand delivering trusted, high-performance energy solutions for a sustainable future.
Residential Energy Storage Solutions Take Center Stage
In addition to commercial offering, Solavita showcased its latest residential energy storage solutions, drawing significant attention from visitors through a live teardown demonstration.
The residential portfolio features a 5–15kW hybrid inverter built for adaptability and resilience. With low startup voltage, a wide operating range, rapid on-grid/off-grid switching under 10 milliseconds, and robust surge protection, it ensures uninterrupted and stable energy supply for households. Its durable design supports long-term reliability with minimal maintenance.
Complementing the inverter, Solavita's high-voltage battery system was also on display. Featuring a modular stackable design, IP65-rated protection, and scalability up to eight modules, the battery system offers homeowners flexibility to expand their storage capacity as needed. Using premium lithium battery cells, the system is engineered for a long service life and dependable performance in all conditions.
With strong showing at Intersolar Europe 2025, Solavita continues to push the boundaries of innovation in distributed energy. Backed by the legacy of Skyworth Group — which also owns well-known brands Metz and Strong in Germany — Solavita is expanding its global footprint, helping more customers achieve smarter, greener, and more sustainable living.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Solavita at Intersolar Europe 2025 - Shaping the Future of Energy
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
